Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Fulcrum Therapeutics Inc
FULC
Healthcare
Biotechnology
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Company’s clinical product candidate, losmapimod, is developed for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Its other clinical product candidate is FTX...
-6058, which is developed for the treatment of certain hemoglobinopathies, including sickle cell disease (SCD). In addition to product candidate development, the Company has developed a drug discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The Company has developed pociredir, which is designed to elevate the level of fetal hemoglobin, or HbF, for the treatment of people with SCD.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:FULC)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
Next
(0)
•••
PressRelease
X
Post by
PressRelease
on Sep 22, 2024 7:01pm
New Press Release - Fulcrum Therapeutics Inc May Have Engaged In Securities Fraud And The Schall Law Firm Encourages Affected Investors To Join An Inquiry
LOS ANGELES, CA / ACCESSWIRE / September 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ:FULC) for violations of the securities laws...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Sep 22, 2024 11:10am
New Press Release - FULC ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Fulcrum Therapeutics, Inc. Shareholders Who Lost Money
NEW YORK, NY / ACCESSWIRE / September 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics, Inc.") (NASDAQ:FULC) concerning possible violations of federal securities laws.Fulcrum announced on September 12, 2024,...
read article.
(301)
•••
whytestocks
X
Post by
whytestocks
on Sep 22, 2024 10:32am
Bronstein, Gewirtz & Grossman, LLC Is Investigating Fulcrum
News; $FULC Bronstein, Gewirtz & Grossman, LLC Is Investigating Fulcrum Therapeutics, Inc. (FULC) And Encourages Investors to ConnectNEW YORK, NY / ACCESSWIRE / September 22, 2024 / Bronstein
...more
(301)
•••
whytestocks
X
Post by
whytestocks
on Sep 20, 2024 10:17pm
Bronstein, Gewirtz & Grossman, LLC Encourages Fulcrum Therap
BREAKING NEWS: $FULC Bronstein, Gewirtz & Grossman, LLC Encourages Fulcrum Therapeutics, Inc. (FULC) Stockholders to Inquire about Securities InvestigationNEW YORK, NY / ACCESSWIRE / September 20,
...more
(301)
•••
whytestocks
X
Post by
whytestocks
on Sep 18, 2024 9:30pm
Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein,
News; $FULC Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the InvestigationNEW YORK, NY
...more
(301)
•••
whytestocks
X
Post by
whytestocks
on Sep 12, 2024 5:30pm
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigatio
BREAKING NEWS: $FULC Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulcrum Therapeutics, Inc.(FULC) And Encourages Stockholders to Reach OutNEW YORK, NY
...more
(301)
•••
whytestocks
X
Post by
whytestocks
on Sep 12, 2024 5:15pm
Fulcrum Therapeutics stock tanks after Phase 3 trial failure
JUST IN: $FULC Fulcrum Therapeutics stock tanks after Phase 3 trial failure of muscular dystrophy drug2024-09-12 10:31:01 ET Fulcrum Therapeutics Inc. (NASDAQ: FULC) saw its stock plunge 65% on
...more
(301)
•••
whytestocks
X
Post by
whytestocks
on Aug 19, 2024 7:17pm
Fulcrum Therapeutics Strengthens Leadership Team with the Ap
Just In: $FULC Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality
...more
(301)
•••
whytestocks
X
Post by
whytestocks
on Jul 31, 2024 2:16pm
Fulcrum Therapeutics Announces Recent Business Highlights an
News; $FULC Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024@ On track to report topline data for Phase 3 REACH trial of losmapimod in
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Sep 22, 2023 8:00am
New Press Release - Fulcrum Therapeutics to Participate at the Cantor Fitzgerald Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Sep 15, 2023 4:30pm
New Press Release - Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Sep 07, 2023 8:00am
New Press Release - Fulcrum Announces Completion of Enrollment in the Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
Enrolled 260 patients; topline data expected in the fourth quarter of 2024 CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases...
read article.
(69)
•••
Iseneschal
X
Post by
Iseneschal
on Aug 23, 2023 1:18pm
FULC .... New new N.H.O.D ; )
read my previous posts Is it time for "The Gap Fill" ?
(69)
•••
Iseneschal
X
Post by
Iseneschal
on Aug 23, 2023 11:18am
FULC ..... New N.H.O.D.... $6.22
and climbing
(69)
•••
Iseneschal
X
Post by
Iseneschal
on Aug 23, 2023 10:27am
FULC ..... N.H.O.D
Get ready ...cause here it comes
Prev
1
2
3
4
5
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Creating a Non-Opioid Solution for Chronic Pain Management